According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 percent) of all deaths in the UK, which equates to more than 160,000 deaths each year — or one death every three minutes.
News | Cardiac Imaging
Using Contrast MRI After a Heart Attack Could Increase Survival

May 12, 2021 — According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 ...

Home May 12, 2021
Home
Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases.
News | Endovascular Aortic Repair
Low Profile Thoracic Aortic Endograft Device Reduces Complications and Expands Patient Pool

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a ...

Home May 12, 2021
Home
EP lab at the University of Colorado
News | EP Lab
Pulsed Electric Field Focal Ablation Catheter From Galaxy Medical and Japan Life Will Seek FDA Clearance 

May 12, 2021 — Galaxy Medical and Japan Lifeline announced an exclusive distribution agreement for the Alpha1 ablation ...

Home May 12, 2021
Home
The digital technology is reducing reliance on unnecessary invasive diagnostic procedures and is cutting hospital waiting times
News | Artificial Intelligence
NICE Renews Support for Use of AI-powered HeartFlow Analysis

May 12, 2021 — HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National ...

Home May 12, 2021
Home
The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.
Is Cardiac Cell Therapy Worth Another Look?

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE) have joined the International Contrast Ultrasound Society (ICUS) in recognizing the relatively low risk and important clinical benefits of ultrasound contrast agents (UCAs), which are used routinely around the world to help detect heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adul
News | Contrast Media
Medical Societies Support Safety and Benefits of Ultrasound Contrast Agents

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease or cardiovascular risk factors, a new Mount Sinai study shows. 
News | Heart Failure
Patients Hospitalized With COVID-19 Have a Small Risk of Heart Failure

May 11, 2021 — Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a ...

Home May 11, 2021
Home
Videos | Structural Heart
VIDEO: VARC-3 Helps Standardize Structural Heart Taxonomy and Research

Philippe Géneréux, M.D., director of the structural heart program at Atlantic Health System’s Morristown Medical Center ...

Home May 10, 2021
Home
The Consumer Technology Association (CTA) is collaborating with the American College of Cardiology (ACC) and several vendors on best practices for device and app and wearable device makers to provide deeper understanding of products that manage cardiovascular health. #wearables
News | Wearables
Vendors and ACC Collaborate With Consumer Technology Association to Help Clinicians and Patients Understand Cardiovascular Devices

May 10, 2021 – Today, the Consumer Technology Association (CTA) announced it is collaborating with the American College ...

Home May 10, 2021
Home
The Eko digital stethoscope can record heart soubnds and use an artificial intelligence  (AI) analysis algorithm to detect heart murmurs. I new study in the JAHA showed it has comparable performance to that of an expert cardiologist. Eko Digital Stethoscope AI Analysis Algorithm Validated in JAHA article for Detecting Heart Murmurs
News | Artificial Intelligence
Eko Digital Stethoscope AI Analysis Algorithm Validated for Detecting Heart Murmurs

May 10, 2021 — Eko announced the peer-reviewed publication of a clinical study that found that the Eko artificial ...

Home May 10, 2021
Home
Videos | Radial Access
VIDEO: Radial Hemostasis Reduced by 50 Percent With StatSeal in Combination With TR Band

Arnold Seto, M.D., MPA, FSCAI, chief of cardiology, Long Beach Veterans Affairs Medical Center and director ...

Home May 06, 2021
Home
Videos | Coronavirus (COVID-19)
VIDEO: The Impact of COVID-19 on Heart Attack Patients

Payam Dehghani, M.D., FRCPC, FACC, FSCAI, co-director of Prairie Vascular Research and associate professor at the ...

Home May 06, 2021
Home
An example of a patch type cardiac monitor from Vital Connect. These types of inexpensive, stick-on wearable monitors have seen a tremendous increase in use over the past few years, replacing traditional Holter monitors.
News | Wearables
Wearable Cardiac Devices Market Will See Rapid Expansion in Coming Years

May 6, 2021 — The wearable cardiac devices market is set to grow from its current market was valued at more than $1.2 ...

Home May 06, 2021
Home
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021
Feature | Cath Lab | By Dave Fornell, Editor
SCAI 2021 Late-breaking Clinical Study Results

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 06, 2021
Home
The Bluegrass Vascular Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. 
News | EP Lab
Case Report on CRT Lead Placement in Obstructed Veins Using Surfacer System

May 6, 2021 - Bluegrass Vascular Technologies announced the publication of a report documenting the clinical utility of ...

Home May 06, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now